

Dilantin®

(diphenylhydantoin)

PARKE-DAVIS

In untold thousands of epileptic patients... Dilantin has been, and continues to be, the bedrock of therapy.

DILANTIN is useful in the treatment of grand mal epilepsy and certain other convulsive states. Its use will prevent or greatly reduce the incidence and severity of convulsive seizures in a substantial percentage of epileptic patients, without the hypnotic and narcotizing effects of many anti-convulsant drugs.

PRECAUTIONS: Periodic examination of the blood is advisable. Nystagmus in combination with diplopia and ataxia indicates dosage should be reduced. The possibility of toxic effects during pregnancy has not been explored.

ADVERSE REACTIONS: Allergic phenomena such as polyarthropathy, fever, skin eruptions, and acute generalized morbilliform eruptions with or without fever. Rarely, dermatitis goes on to exfoliation with hepatitis, and further dosage is contraindicated. Gingival hypertrophy, hirsutism, and excessive motor activity are occasionally encountered. During initial treatment, side effects may include gastric distress, nausea, weight loss, nervousness, sleeplessness, feeling of unsteadiness. Macrocytosis, megaloblastic anemia, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, agranulocytosis, and aplastic anemia have been reported. Nystagmus, lymphadenopathy, lupus erythematosus, erythema multiforme (Stevens-Johnson syndrome), and a syndrome resembling infectious mononucleosis with jaundice have occurred. DILANTIN is supplied in several forms including Kapseals® containing 0.1 Gm. and 0.03 Gm. diphenylhydantoin sodium.

Parke, Davis & Company, Detroit, Michigan 48232

The color combinations of the banded capsules are Parke-Davis trademarks. The orange-banded white capsule identifies Parke-Davis 0.1 Gm. diphenylhydantoin sodium; the pink-banded white capsule 0.03 Gm. diphenylhydantoin sodium.

PARKE-DAVIS

015R67



1969 ANNUAL SCIENTIFIC ASSEMBLY

OF THE CALIFORNIA MEDICAL ASSOCIATION

Ambassador Hotel
Los Angeles, March 15-19

EIGHTEEN SCIENTIFIC SECTION PROGRAMS ON A VARIETY OF TOPICS PLUS THREE GENERAL MEETINGS ON THE SUBJECTS:

RECOGNITION AND TREATMENT

- STROKE
- NEONATAL AND CONGENITAL DISEASES
- METABOLIC DISEASES

FIRST CALL FOR MATERIAL

SCIENTIFIC PAPERS • MEDICAL MOTION PICTURES • SCIENTIFIC EXHIBITS

★ **If you have a paper** you'd like to present to your colleagues during their section meeting . . . write today to your section secretary (names and addresses of scientific section officers may be found on page 6, Advertising Section of **California Medicine**). Presentations are not limited to the themes of the general meetings.

★ **If you have a motion picture or exhibit** . . . write to the California Medical Association Committee on Scientific Assemblies, 693 Sutter Street, San Francisco 94102 for application forms.

PLANS FOR THE 1969 ANNUAL SCIENTIFIC ASSEMBLY ARE NOW IN PROGRESS
PLAN **YOUR** CONTRIBUTION TO THE PROGRAM **TODAY**